NCT07099976 PromotIng Optimal Treatment for Community-acquired PNeumonia in EmErgency Rooms
| NCT ID | NCT07099976 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Jeffrey Pernica |
| Condition | Community-Acquired Pneumonia (CAP) |
| Study Type | INTERVENTIONAL |
| Enrollment | 698 participants |
| Start Date | 2026-04-15 |
| Primary Completion | 2030-04-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 698 participants in total. It began in 2026-04-15 with a primary completion date of 2030-04-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In North America, up to 5% of preschoolers develop community-acquired pneumonia (CAP) every year. Pneumonia is the second-leading reason for paediatric hospitalization in both Canada and the US; approximately 20% of children hospitalized with CAP may need intensive care, which can result in significant morbidity. Given this burden of disease, it is critical that CAP is managed appropriately. Specific therapy for CAP is dependent on microbiologic aetiology, as bacterial disease will improve with antibiotic treatment.
Eligibility Criteria
Inclusion Criteria: Children aged 6 month to 18 years presenting to the Emergency Department who are diagnosed with CAP and are well enough to be discharged home (i.e. 'non-severe' CAP) will be eligible. They must have a fever (on exam or by history) and at least one of: * Tachypnoea measured at triage (\>60 bpm for age \<1, \>50 for 1-2 years of age, \>40bpm for 2-4 years of age, and \>30bpm for \>4 years of age) * Cough on exam or by history * Increased work of breathing on exam * Auscultatory finding (focal crackles, bronchial breathing, etc.) consistent with CAP Exclusion Criteria: Children will be excluded if they have any of the following * Cystic Fibrosis * Anatomic Lung Disease * Bronchiectasis * Chronic Lung Disease requiring home oxygen or home ventilation * Congenital heart Disease (requiring specific medical treatment or with exercise restrictions), * History of repeated aspiration/velopharyngeal incompetence * Malignancy * Immunodeficiency (primary, acquired or iatrogenic) * Pneumonia previously (clinically) diagnosed within the past month (that was presumed to have resolved prior to the episode prompting the current visit to the ED) * Lung abscess within the past 6 months * Children who present with ongoing fever after 4 days of amoxicillin, cefprozil, cefuroxime, levofloxacin, moxifloxacin or doxycycline are not eligible; as this duration of therapy with these drugs would normally be sufficient to treat bacterial CAP, a different approach would be required (ie. the care pathway as written might not be appropriate). * Children will not be eligible to participate more than once
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07099976 clinical trial?
This trial is open to participants of all sexes, aged 6 Months or older, up to 18 Years, studying Community-Acquired Pneumonia (CAP). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07099976 currently recruiting?
Yes, NCT07099976 is actively recruiting participants. Contact the research team at pernica@mcmaster.ca for enrollment information.
Where is the NCT07099976 trial being conducted?
This trial is being conducted at Calgary, Canada, Edmonton, Canada, Vancouver, Canada, Hamilton, Canada and 2 additional locations.
Who is sponsoring the NCT07099976 clinical trial?
NCT07099976 is sponsored by Jeffrey Pernica. The trial plans to enroll 698 participants.